COMMUNIQUÉS West-GlobeNewswire

Argos Provides Financial Update

28/11/2017 - 14:00

DURHAM, N.C., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ: ARGS ), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis [...]

TESARO Announces Availability of VARUBI® (rolapitant) IV for Delayed Nausea and Vomiting Associated With Cancer Chemotherapy in the United States

28/11/2017 - 14:00

VARUBI injectable emulsion features ready-to-use, single-dose vial No saline, reconstitution or mixing is required to utilize VARUBI IV New formulation offers healthcare providers flexibility in their choice of [...]

PhaseBio Enters Worldwide License Agreement with MedImmune for a Reversal Agent for Ticagrelor

28/11/2017 - 14:00

First-in-class and unique reversal agent for ticagrelor aims to address important unmet need for patients requiring antiplatelet therapy Potential for accelerated development timeline with Phase 1 initiation expected in [...]

Provant Vice President of Client Management Elizabeth Merritt, Esq., is featured prominently in a recent Bloomberg Law article on wellness program incentives

28/11/2017 - 14:00

EAST GREENWICH, R.I., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Provant Vice President of Client Management Elizabeth Merritt, Esq., is featured prominently in a recent Bloomberg Law article on wellness program incentives. [...]

Neos Therapeutics to Participate in Two December Conferences

28/11/2017 - 14:00

DALLAS and FORT WORTH, Texas, Nov. 28, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS ), a pharmaceutical company focused on developing, manufacturing, and commercializing innovative extended-release (XR [...]

Athenex Announces Acceptance of Phase II Data of KX2-391 for the Treatment of Actinic Keratosis for Presentation at the American Academy of Dermatology Meeting on February 17, 2018

28/11/2017 - 14:00

BUFFALO, N.Y., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX ), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of [...]

Zogenix To Host Call with Pediatric Epilepsy Expert Joseph Sullivan, M.D., on Dravet Syndrome and ZX008 on Monday, December 4

28/11/2017 - 14:00

EMERYVILLE, Calif., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX ), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that [...]

PositiveID Projects Revenue Growth of More Than 30% Year-over-Year through First Quarter of 2018

28/11/2017 - 14:00

DELRAY BEACH, Fla., Nov. 28, 2017 (GLOBE NEWSWIRE) -- PositiveID Corporation (OTC:PSID), a life sciences company focused on detection and diagnostics, today announced that it projects consolidated year-over-year revenue [...]

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

28/11/2017 - 14:00

ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 28, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP ), a genome editing company focused on creating transformative medicine for serious diseases, today announced [...]

Transactions in relation to share buyback program

28/11/2017 - 13:50

Acting under its share buyback authorization, the GN Store Nord board of directors initiated a share buyback program on May 4, 2017 in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]

Arch Therapeutics to Provide Corporate Update at the 10th Annual LD Micro Main Event In Los Angeles December 5-7, 2017

28/11/2017 - 13:50

FRAMINGHAM, Mass., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will be featured as a [...]

Cesca Therapeutics Announces Issuance of Second Cellular Processing Patent

28/11/2017 - 13:30

RANCHO CORDOVA, Calif., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ: KOOL ), a market leader in automated cell processing today announced that on November 21, 2017, the U.S. Patent and Trademark [...]

Aptevo Therapeutics Announces Plans to Conduct Phase 2 Study of Otlertuzumab in Peripheral T-Cell Lymphoma

28/11/2017 - 13:02

Anticipates 2 IND Filings in 2018 for Novel Bispecific Antibody Candidates SEATTLE, Nov. 28, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq: APVO ), a biotechnology company focused on developing novel [...]

Aurora Spine Corporation Files Condensed Consolidated Financial Statements for the Three and Nine Months Ended September 30, 2017

28/11/2017 - 13:00

CARLSBAD, Calif., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV:ASG) announces financial results for the three and nine months ended September 30, 2017. To our [...]

Deciphera Pharmaceuticals, Inc. Announces Orphan Drug Designation from the EMA for DCC-2618 for the Treatment of Gastrointestinal Stromal Tumors

28/11/2017 - 13:00

WALTHAM, Mass., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH ) a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance, today announced [...]

G1 Therapeutics and AstraZeneca Enter Clinical Trial Collaboration in Non-Small Cell Lung Cancer

28/11/2017 - 13:00

RESEARCH TRIANGLE PARK, N.C., Nov. 28, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ: GTHX ), a clinical-stage oncology company, today announced a clinical trial collaboration with AstraZeneca to evaluate [...]

Axsome Therapeutics Announces AXS-07 for the Treatment of Migraine

28/11/2017 - 13:00

Incorporates new molecular entity for migraine and Axsome’s MoSEIC™ technology Potential for superior efficacy as compared to current treatments FDA Pre-IND meeting written guidance received Issued U.S. patent provides [...]

ALK to launch updated corporate strategy on 4 December

28/11/2017 - 12:50

Copenhagen, 2017-11-28 12:50 CET (GLOBE NEWSWIRE) -- On Monday, 4 December 2017, ALK ( ALKB:DC / OMX: ALK B / AKABY / AKBLF ) will present its updated corporate strategy. That day at 11.00 a.m. (CET), ALK will host a [...]

ReWalk Robotics Announces Full Exercise of Underwriter’s Option to Purchase Additional Ordinary Shares in Follow-on Public Offering

28/11/2017 - 12:50

YOKNEAM ILIT, Israel and MARLBOROUGH, Mass., Nov. 28, 2017 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq: RWLK ) (“ ReWalk ” or the “ Company ”) today announced that National Securities Corporation (“ National ”), [...]